A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer

Chinese Medical Journal

Volumn 125, Issue 16, 2012, Pages 2902-2907

  Wei, Hai bo ^a   Hu, Jing ^a   Shang, Li hua ^a   Zhang, Yun yan ^a   Lu, Fei fei ^a   Wei, Min ^a   Yu Dr , Yan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; ERCC1; MDR1; Meta analysis; Non small cell lung cancer; Platinum based

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; PACLITAXEL; PEMETREXED;

ADVANCED CANCER; ARTICLE; CHEMOSENSITIVITY; CLINICAL TRIAL (TOPIC); GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; P-GLYCOPROTEIN; PLATINUM; POLYMORPHISM, GENETIC;

EID: 84865362198     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.16.019     Document Type: Article

References (32)

1. Kelly K, Crowley J, Bunn PA, Jr., Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
3. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 8-58.
4. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002; 62: 4899-4902.
5. Rosell R, Taron M, Ariza A, Aurelio A, Barnadas A, Mate JL, et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 2004; 31: 20-27.
6. Terek MC, Zekioglu O, Sendag F, Akercan F, Ozsaran A, Ersan Y. MDR1 gene expression in endometrial carcinoma. Int J Gynecol Cancer 2003; 13: 637-677.
7. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003; 10: 43-73.
8. Sauna ZE, Smith MM, Muller M, Kerr KM, Ambudkar SV. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001; 33: 481-491.
9. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 2002; 25: 1391-1400.
10. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 2006; 12: 273-286.
11. Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J 2001; 1: 59-64.
12. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473-3478.
13. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/ cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001; 11: 175-184.
14. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 2008; 75: 380-385.
15. Ryu JS, Hong YC, Han HS, Lee JE, kim S, Park YM, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44: 311-316.
16. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004; 15: 1194-1203.
17. Su D, Ma S, Liu P, Jiang J, Lü W, Zhang Y, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007; 56: 281-288.
18. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008; 14: 1797-1803.
19. Gao CM, Shi MQ, Wu JZ, Cao HX, Feng JF, Xu L. Polymorphisms in ERCC1, XRCC1 genes and sensitivity to gemcitabine/cisplatin chemotherapy in non-small cell lung cancer. Chin J Cancer Prev Treat (Chin) 2010; 16: 27-30
20. Chen S, Huo X, Lin Y, Ban H, Li W, Zhang B, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 2010; 213: 140-145.
21. Li XH, Jiang WF, Zhang HL, Zhang J. Relationship between SNPs of ERCC1 in peripheral blood of NSCLC and effects of cisplatin-based chemotherapy. Chin J Cancer Prev Treat (Chin) 2010; 17: 169-172.
22. Su T, Zhao LJ, Chang WJ, Wang GP, He YC, Sun QY, et al. Relationship of ERCC1, XPD, and BRCA1 polymorphisms with efficacy of platinum-based chemotherapy for patients with advanced non-small cell lung cancer. Acad J Second Milit Med Univ (Chin) 2010; 31: 117-122.
23. Wang JH, Zhang Q, Zhang H, Wang QH, Yang XJ, Gu YF, et al. Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy. Chin J Lung Cancer (Chin) 2010; 13: 337-341
24. Yu QZ, Han JX, Pan JH, Sheng LJ, Wu JM, Huang HN. The relationship between the polymorphisms of gene XGP and MDR1 and the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy. Pract J Cancer (Chin) 2007; 22: 252-256.
25. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009; 10: 118-123.
26. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009; 27: 3540-3546.
27. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006; 333: 597-600.
28. Nadkar A, Pungaliya C, Drake K. Therapeutic resistance in lung cancer. Exper Opin Drug Metab Toxicol 2006; 2: 753-777.
29. Lenz HJ. The use and development of germline polymorphisms in clinical oncology. J Clin Oncol 2004; 22: 2519-2521.
30. Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer 2004; 90: 8-11.
31. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999; 22: 231-238.
32. Marsh S, Kwok P, McLeod HL. SNP databases and pharmacogenetics: great start, but a long way to go. Hum Mutat 2002; 20: 174-179.